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Abstract Dilation of the wall of the thoracic aorta can be
found in patients with a tricuspid (TAV) as well as a bicuspid
aortic valve (BAV) with and without a syndromic component.
BAV is the most common congenital cardiovascular malfor-
mation, with a population prevalence of 0.5–2 %. The clinical
course is often characterised by aneurysm formation and in
some cases dissection. The non-dilated aortic wall is less well
differentiated in all BAV as compared with TAV, thereby
conferring inherent developmental susceptibility. Further-
more, a turbulent flow, caused by the inappropriate opening
of the bicuspid valve, could accelerate the degenerative pro-
cess in the aortic wall. However, not all patients with
bicuspidy develop clinical complications during their life.
We postulate that the increased vulnerability for aortic com-
plications in a subset of patients with BAV is caused by a
defect in the early development of the aorta and aortic valve.
This review discusses histological and molecular genetic as-
pects of the normal and abnormal development of the aortic
wall and semilunar valves. Aortopathy associated with BAV
could be the result of a shared developmental defect during
embryogenesis.
Keywords Aortopathy . Bicuspid aortic valve . Embryology
Introduction
Aortic dilation is a pathological widening of the aorta, which
can be found in a thoracic (TAD) and abdominal (AAD) form
according to its location. In contrast to AAD, TAD is usually
not related to atheroma and often occurs at a younger age [1].
Different aetiologies have been described which predispose
individuals for TAD, involving monogenic syndromes, such
as Marfan (MFS), Ehlers-Danlos (EDS), Smad3 mutations
and Loeys-Dietz (LDS) syndromes, sometimes accompanied
by bicuspid aortic valve (BAV) as well as idiopathic causes
[2], while BAV is also found as an isolated anomaly.
Although patients with isolated BAV may remain asymp-
tomatic, in a significant proportion of the patients the clinical
course is accompanied by aortic stenosis, aortic regurgitation,
infective endocarditis, and TAD which has a prevalence as
high as 50–60 % [3]. Particularly, TAD forms a critical com-
plication, as it carries a risk of dissection and rupture, making
it a potentially lethal disease.
Considering these clinical complications, understanding of
the development of the ascending aorta and both normal and
abnormal aortic valves is mandatory. By sharing a number of
embryonic cell types the development of the ascending aorta
is narrowly related to the development of the aortic valve.
Hence, aortopathy associated with BAV could be the result of
a combined developmental defect in early embryogenesis. It
has to be kept in mind, however, that not all individuals with
BAV develop TAD. In search of the pathogenesis of aortic
complications in BAV, the focus has recently shifted towards
defining patients susceptible for aortopathy needing aortic
intervention.
This review discusses several aspects of normal and abnor-
mal development of the aortic wall and aortic semilunar
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valves. We hypothesise that the increased vulnerability for
aortic complications in BAV is caused by a defect in the early
development of the aorta and aortic valve.
General overview of normal and abnormal aortic valve
and aorta development
During organogenesis the first functional organ to form is the
heart. The first sign of valvulogenesis is the formation of
endocardial cushions in the atrioventricular canal and outflow
tract. The atrioventricular cushions contribute to the atrioven-
tricular (mitral and tricuspid) valve leaflets, whereas the out-
flow tract cushions contribute to the semilunar (aortic and
pulmonary) valve leaflets [4]. Development of semilunar
valves is a complex process in which neural crest cells, second
heart field (SHF) progenitors and endocardial cushion derived
cells play a role (Fig. 1). The developmental origin of the
endocardial cushion cells themselves has been a matter of
debate in the past years. Recent lineage tracing studies with
Nkx2.5 [5] have shown that SHF progenitor cells give origin
to three specific cell lines: 1. vascular smooth muscle cells
(VSMCs) of the great arteries, 2. outflow tract and right
ventricular myocardium, and to 3. the much discussed
endothelial-derived endocardial cushion cells, which are in
part derived from the endothelium [5]. Recently, Harmon
et al. presented data on the boundary where SHF-derived
VSMC meet neural crest cell-derived VSMC at the base of
the aorta [5]. The SHF contribution to the aortic media then
forms a vertical seam complementary with neural crest-
derived VSMC [5]. Next to contributing to the vascular wall,
a population of neural crest cells migrates to the outflow tract
cushions where they are important for semilunar valve forma-
tion and outflow tract septation [6, 7]. Preliminary data show a
contribution of the arterial epicardium to the VSMCs of the
ascending aorta [8].
During valvulogenesis several signalling pathways such as
Wnt/β-catenin, NOTCH, transforming growth factor β
(TGF-β), bone morphogenetic protein (BMP), vascular endo-
thelial growth factor (VEGF), NFATc1 and MAPK, as well as
transcription factors, including Twist1, Tbx20, Msx1/2, and
Sox9, are necessary for the regulation of cell migration, pro-
liferation, and extracellular matrix deposition in the develop-
ing valves [9–12].
As a consequence, more than one cell population that
contributes to both aortic wall and semilunar valve formation
may be involved in the development of bicuspidy. Clinically,
several BAV subtypes are distinguished on the basis of the
fused commissure or raphe position. Type 1: raphe between
right coronary cusp (RCC) and left coronary cusp (LCC), type
2: between RCC and non-coronary cusp (NCC) and type 3:
raphe between LCC and NCC (Fig. 2). Clinical outcome
differs between the valve types, supporting a different devel-
opmental background as underlying cause. Recent support for
the role of deficient neural crest cell contribution in develop-
ment of type 1 BAVwas seen in the Rock 1,2 deficient mouse
[6]. Fernandez et al. argued that type 1 and type 2 BAVs have
a different pathogenesis [13]. An altered neural crest cell
behaviour was suggested to be responsible for the develop-
ment of type 1 BAVs and the endothelial nitric oxide (eNOS)
mutation for type 2 BAV. eNOS is expressed by endocardial
cells [14], cardiomyocytes [14] and VSMCs [15], all SHF-
derived cell types/populations, indicating a role for SHF pro-
genitors in the development of type 2 BAV. Another role for
SHF in the development of type 2 BAV was demonstrated by
endocardial specific deletion of the gene encoding for the
activin type I receptor (ALK2) [16].
Other genetic defects leading to BAV have been identified
with selective knockout of genes in murine models but have
not focused on the differentiation in type 1 or type 2 BAVs.
From the recognised genes, Pax3 is a marker of neural crest
cells [17]. Furthermore, the identified SHF markers Nkx2.5
and GATA5 (endocardial cell-specific) are associated with the
development of BAV [18].
Abnormalities of NOTCH signalling in the neural crest
[19] or SHF can also contribute to the development of abnor-
mal semilunar valves [17, 20]. Interestingly, inhibition of
NOTCH in SHF impairs fibroblast growth factor 8 (Fgf8)
signalling, which results in the development of BAV, but also
in VSMC abnormalities of the great arteries [21]. Therefore,
Fig. 1 Schematic overview of the developing heart tube. The second
heart field (SHF) is indicated contributing to the arterial pole of the heart
including the great vessels and the right ventricle by the anterior popula-
tion (AHF). At the venous pole SHF cells are entering from the posterior
population (PHF). Both at the venous (vPEO) and arterial (aPEO) pole a
proepicardial organ provides the epicardial cells that cover the myocar-
dium and the intrapericardiac part of the great vessels. Neural crest cells
migrate from the neural tube primarily to the arterial pole of the heart
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we postulate that a developmental defect of various progenitor
cell lines may provide a common mechanism underlying
aortic valvulopathy (BAV), as well as aortopathy. The next
section focuses on genetic defects described in BAVand TAD
in human and their origin in embryogenesis.
Genetic basis of BAV and TAD
Consistent data have suggested a genetic cause of BAV dis-
ease [22, 23]. Despite high heritability it remains challenging
to determine the underlying mechanism of BAV in the human
population, supported by murine data, as it is probably due to
interacting mutations in diverse genes encoding transcription
factors, extracellular matrix (ECM) proteins and signalling
pathways that regulate cell proliferation, differentiation, adhe-
sion or apoptosis.
Although a remarkable reduction in eNOS levels was seen
in BAV patients, this could not be correlated to a mutation in
the eNOS gene [24]. Moreover, mutations in the NOTCH1
gene, which is expressed by both neural crest and SHF, and
mapped to chromosome 9q34, have been associated with the
development and progression of BAV [19, 25]. Further genet-
ic haplotypes within the AXIN1-PDIA2 locus have been
recognised that strongly associate with BAV. AXIN1 (Axis
Inhibitor 1) is a critical member of the Wnt pathway, which
regulates both heart valve formation [26] and cardiac neural
crest development [27]. Another haplotype within the
Endoglin gene (known as a co-receptor in the TGFβ pathway)
is required for differentiation of neural crest cells into VSMCs
that populate the aorta [28].
From these genetic defects we conclude that there is a clear
link to defects in neural crest as well as SHF-derived cell
populations with elements for BAV. Alterations in neural crest
Fig. 2 Overview of our hypothesis on the developmental origin of the
bicuspid aortic valve and aortic wall abnormalities Figure 2 provides a
schematic presentation of the aortic bicuspidy valve types based on the
valve leaflet orientation and the position of the raphe. Type 1: with fusion
between the right coronary cusp (RCC) and left coronary cusp (LCC).
Type 2: with fusion between the RCC and non-coronary cusp (NCC).
Type 3 with fusion between the LCC and NCC. Furthermore an overview
of our hypothesis on the developmental origin of the bicuspid aortic valve
and aortic wall abnormalities is provided. Previously identified genetic
mutations in mice (Nkx2.5, Alk2, eNOS, GATA5, NOTCH, Fgf8,
Rock1,2 and Pax3) and in human (NOTCH) resulting in bicuspid aortic
valves (BAV) are indicated in this figure. These genetic defects can be
subdivided in either second heart field (SHF) or neural crest cell related.
SHF and neural crest cells both contribute to the vascular smooth muscle
cells in the ascending aorta as well as to the cells involved in semilunar
valve formation. The SHF most probably also contributes to the endo-
cardial cells of the cardiac outflow tract. Therefore these early develop-
mental defects can cause bicuspidy, but also explain the less well differ-
entiated aortic wall seen in all patients with a BAV. However, not every
patient with BAV has increased susceptibility for aortopathy. Therefore an
additional factor needs to be identified to recognise patients with in-
creased vulnerability for aortic complications
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signalling are associated with the most common type 1 BAV
[29], identified as the valve type with most severe aortic
wall abnormalities as compared with the other valve types
[13, 30, 31] while SHF-related genes seem to correlate more
with BAV type 2.
This brings us to the next important question whether TAD,
not necessarily accompanied by BAV, is related to defects in
neural crest signalling or alternatively, is there a more specific
role for the SHF-derived cells? The following section concen-
trates on genetics of TAD in syndromes including Marfan,
Ehlers-Danlos, Smad3 mutations and Loeys-Dietz and their
link to embryonic development.
Marfan syndrome (MFS) is a connective tissue disorder
characterised by cardiovascular, skeletal and ocular man-
ifestations. The progressive dilation of the aortic root
culminating in dissection is a major cause of morbidity
and mortality in MFS patients. This syndrome is the result
of a defect in the fibrillin-1 (FBN1) gene that localises on
chromosome 15q21.1 and is inherited in an autosomal
dominant manner [32]. A second locus for Marfan syn-
drome (MFS2) has been mapped to chromosome 3p25-
24.2, and a heterozygous mutation in TGFΒR2 was sub-
sequently identified as the genetic defect [33]. The
TGFBR2 mutations in MFS patients involve the serine-
threonine kinase domain and reduce TGFβ-induced re-
ceptor signalling.
Loeys-Dietz (LDS) is caused by another defect in the
TGFβ signalling pathway. In this syndrome TGFBR1
and TGFBR2 mutations are mapped to chromosome
9q33-34 and 3p24-25 respectively. Cardiovascular lesions
in LDS include aortic valve regurgitation and aortic
root dilation, aneurysm formation and dissection. Other
phenotypic characteristics include craniosynostosis, cleft
palate, bifid uvula, congenital heart disease and mental
retardation.
Another syndrome presenting with aneurysms, dissec-
tions and tortuosity throughout the arterial tree in associ-
ation with mild craniofacial features and skeletal and
cutaneous anomalies has recently been described by Van
de Laar et al. [34]. The genetic locus has been mapped to
chromosome 15q22.2-24.2 and shows that the disease is
caused by mutations in SMAD3, essential for propagation
of the TGF-β signal to the nucleus and activation of
downstream gene transcription.
An additional syndrome worth mentioning is Ehlers-
Danlos (EDS). Patients with vascular EDS often present
with dissection or rupture of the thoracic aorta. Aortic
dissections have been reported in at least 10 % of patients
with EDS [35]. This syndrome is attributed to a mutation
in the gene encoding type III procollagen (COL3A1),
mapped to 2q24.3-q31 [36]. Type I and type III collagen
are the most abundant collagen fibres found in the media
and adventitia of the aortic wall. In addition to providing
mechanical strength, collagen has other functional prop-
erties, including activation of intracellular signalling cas-
cades, storage of soluble factors, such as IL-2, and regu-
lation of their local activity [37].
Furthermore, TAD occurs in association with an auto-
somal dominant disorder in the absence of syndromic
features, termed FTAAD (familial thoracic aortic aneu-
rysm and dissection). A variety of genetic loci have been
identified in this regard, such as TAAD1 locus, on chro-
mosome 5q 13-14 [38] and TAAD2 locus on chromosome
3p24-25 [39], the mutant gene associated with this locus
is TGFBR2. Only 5 % of investigated families have this
mutation, suggesting a relatively rare cause [39]. TAAD3
locus on chromosome 15q24-26 [38, 39] and TAAD4
locus on chromosome 10q23-24 are also related to the
development of aortic dissection. In the latter ACTA2
encoding for VSMC a-actin is identified [40]. The muta-
tions impair the function of the VSMCs and this affects
the integrity of the vessel wall, making it prone to dila-
tion. This mutation has also been associated with an
increased activity of the TGFβ pathway in the aorta
[41]. In TAAD5 the identified gene is TGFBR1, mapped
to chromosome 9q33-34 [42].
In most of the above TAD cases an increased TGFβ
activity has been identified. However, TGFβ is not spe-
cific for neural crest, as it is also clearly involved in the
endothelium and the SHF-derived cell populations [43].
In syndromes as MFS, EDS, and LDS, bicuspidy is not an
obligatory clinical manifestation, indicating that a defec-
tive TGFβ signalling is at least not the main factor caus-
ing BAV formation. Neural crest defects seem to cause the
most frequently occurring type 1 BAV which is associated
with most marked complications of the aortic wall, and
often with an increased TGFβ activity [44]. However, the
clinical course is not complicated with TAD in all BAV
patients. Thus, neural crest involvement and TGFβ activ-
ity together are not sufficient to explain the variability
within the pathogenesis of BAV and associated
aortopathy. Additional pathogenetic factors need to be
taken into account such as haemodynamics or a contribu-
tion of SHF.
Pathogenesis of TAD in BAV: role of haemodynamics
and SHF
The morphology of the bi-leaflet valve produces a nonaxial
transvalvular turbulent flow jet within the aortic root [45].
This turbulent flow, along with other haemodynamic factors,
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as an increased stroke volume (for instance aortic regurgita-
tion), have been suggested to facilitate developing aortic com-
plications, as the created abnormal biomechanics and helical
flow alterations lead to an uneven wall stress distribution.
However, several studies have confirmed that ascending aortic
aneurysms can develop in the absence of valve abnormality
[46]. Moreover, Yasuda et al. have reported development of
aortic dilation after surgical repair of the diseased bicuspid
aortic valve [47]. These studies suggest that structural wall
abnormalities at the cellular level may be important for the
onset of dilation. Therefore, haemodynamic factors alone are
not sufficient to explain the pathogenesis of aortopathy asso-
ciated with bicuspid aortic valves.
The alternative hypothesis is that genetically determined
abnormalities of the aortic wall lead to a defect in the cellular
microenvironment, causing or at least contributing to the
aortic pathology and render the wall vulnerable to haemody-
namic stress.
Several studies have focused on differences between
the dilated aortic wall in BAV and TAV. Histopathological
features of the aortic wall in BAV show decreased medial
inflammation, elastin fragmentation and cystic medial ne-
crosis, when compared with TAV [48]. In addition, the
aortic wall has a different composition in BAV, with a
significantly thicker tunica media but significantly thinner
tunica intima [49]. In recent years research on ECM com-
position mainly established differences in the aortic media
of dilated aortic wall in BAV and TAV [25, 38]. To take a
step further in unravelling a possible different pathogenet-
ic mechanism of TAD in BAV and TAV, we investigated
non-dilated aortic walls of both valve types. The aortic
media was specifically studied for maturation of VSMCs
and ageing characteristics. We concluded that TAD in
TAV has aspects of ageing, whereas in bicuspidy there is
a defective smooth muscle cell differentiation (Fig. 3)
unrelated to ageing. These results suggest that the funda-
mental difference in the aortic wall make-up of BAV is
found in less differentiated VSMCs as compared with
TAV while still both neural crest cells and SHF contribute
to the VSMCs in the aortic wall. Haemodynamic factors
might play a role in the aortic complications, but
superimposed on the already present structurally immature
aortic wall seen in BAV.
Conclusion and future perspectives
From a clinical point of view, aortic complications vary
between the different BAV types. Aortic root diameters for
instance have been analysed between BAV type 1 and 2 in
several studies, all of which found larger aortic root diam-
eters in the type 1 [13, 30, 49], being more vulnerable for
degradation [31]. Type 2 BAVs are responsible for valve
dysfunction at a younger age [30, 49]. Aortopathy seems
most outspoken in BAV type 1, probably being caused by
a defect in neural crest. Despite these recent findings
however, clinical parameters have not been conclusive in
distinguishing patients with BAV susceptible for
aortopathy, suggesting that an alternative, molecular bio-
logical approach might be necessary.
In this review we describe that altered neural crest cell
and second heart field contribution, separately or in combi-
nation, can account for a structurally different aortic wall in
combination with bicuspidy (Fig. 2). Figure 2 summarises
that defects in neural crest cells are mostly associated with
type 1 BAV and defects in SHF with type 2. These contri-
butions alone, however, are not sufficient to explain the
clinical heterogeneity seen in BAV patients, as not all indi-
viduals with BAV develop aortic complications during their
life. Therefore, additional factors make the aorta susceptible
for ensuing complications. It is important to determine
Fig. 3 Defective smooth muscle cell differentiations in bicuspidy. Trans-
verse histological sections of the media of the aortic wall stained for the
smooth muscle cell marker alpha smooth muscle actin (αSMA). In patients
with a tricuspid aortic valve and a dilated aortic wall (TAD) the expression
of this marker is higher as compared with the expression in patients with a
bicuspid aortic wall and dilated aortic wall (BAD). Furthermore the aortic
media in TAD shows significantlymore pathology as comparedwith BAD,
with profoundly more cystic medial necrosis (CN) defined as loss of
smooth muscle cell nuclei. Magnification bar: 500 μm
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which developmental defect accounts for the additional pa-
thology making the aortic wall susceptible for TAD. Future
research, therefore, needs to focus on identifying molecular
pathways related to neural crest and SHF. These factors are
required to distinguish a susceptible and a non-susceptible
group for suspected aortic complications.
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